The attenuation of therapeutic benefit persisted despite ongoing CY12-RP2 administration during intermittent anti-CD8 treatment, with tumor volumes and body weight (with <5% variance) monitored throughout the experiment. The gene discussed is CD8A; the disease is neoplasm.